Hanmi Pharmaceutical, Genentech, Roche deal

Hanmi granted Roche’s Genentech unit exclusive, worldwide rights outside of South Korea to develop and commercialize HM95573 -- a selective pan-Raf inhibitor in Phase I development to treat solid tum...